A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A group of Victorian mothers have written to the health minister after struggling to get their children an antibody ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...